Tweet

Biotech2k

3 Oct, 8 tweets, 2 min read

Profiling $CCCC:

I just recently started investing in this company. I don't know very much about the management yet. They do have a broad pipeline of targets around oncology using both heterobifunctional and molecular glues.

1/ Their lead indication is a molecular glue that binds to the CRBN E3 ligase and target IKZF1 and IKZF3 transcription factors. This is in development for Multiple Myeloma. This is a nice size indication where Revlimid earns about $2 billion per year in this space.

2/ Their second drug is a heterobifunctional molecule targeting the BRD4 protein. This is an protein that plays a role in DNA packaging and gene expression. The indications for this drug seem very small.

3/ Their 3rd drug is for EFGR L858R mutations. This makes up 41% of the EFGR mutations. They also claim it should also hit T790M and C797S mutations that develop from kinase inhibitors.

4/ I think this one could be huge if it can do everything osimertinib does and does it with a far safer profile. This is one space where I think protein degraders could replace and take share from kinase inhibitors. They need to do the same efficacy with cleaner safety.

5/ Osimertinib sales over $3 billion a year. Based on how well they compete on efficacy, they could take a large share of that. They are also working on BRAF V600E and RET inhibitors.

6/ Right now we have no data from $CCCC with any of its indications. It has a ton of potential but no validation yet.

7/ I think $2.2 billion valuation is very high for a company with no data. I think the valuation should be closer to $1.5 billion or $30 per share. That makes it quite expensive until we see some data that validates the science.

• • •

Missing some Tweet in this thread? You can try to force a refresh

This Thread may be Removed Anytime!

Twitter may remove this content at anytime! Save it as PDF for later use!

More from @Biotech2k1

Biotech2k

@Biotech2k1

5 Oct

My game plan updated:

I am still into the buy the dips and sell every rip. I think the collapse in the bubbles in the biotech space are just getting started.

Pathways:

$BPMC 3.36% core position
$TPTX 3.36% core position
$RVMD 2.02% expendable into any big rally
$ERAS 1.34% expendable into any big rally
$RLAY 2.02% expendable into any big rally

Synthetic Lethality:

$MRTX 3.36% core position
$SDGR 2.02% working to pay off core position
$RPTX 2.69% working to pay off core position

Read 7 tweets

Biotech2k

@Biotech2k1

4 Oct

Profiling $CABA:

I have been in this company for about 8 months now. I think the management is good, but way too early to tell. They are my small cap high risk play.

1/ They are using CAAR-T to target autoimmune disorders. They use a CAAR receptor that encodes a self antigen that drives auto immune disease. The concept is the self reactive B cells should target binding to the CAAR receptor and the T cell would kill them.

2/ Based on the really low level of memory B cells in the body, it could be very difficult to clear them out. Its a high risk play, but if it works, it could be a huge opportunity.

Read 5 tweets

Biotech2k

@Biotech2k1

4 Oct

Profiling $TIL:

This is a newer company that just went off its lock up period. I don't know the management that well, but it can't be any worse than the disastrous $IOVA. That company is completely broken.

1/ They are working on Tumor Infiltrating Lymphocytes (TIL). This is the most successful use of TCR therapies in solid tumors. This starts with removing a met or doing a biopsy of the tumor. It takes that tumor and breaks it down to get all the antigens for that specific patient.

2/ Those tumor antigens are introduced to the patient's own T cells in the lab to activate them toward those antigens. Those T cells are then put back into the patient with PD1 to target and kill all tumor cells and mets.

Read 7 tweets

Biotech2k

@Biotech2k1

4 Oct

Profiling $CRBU:

This is a new IPO and they are still within the lock up period until late January. I have followed them as a private company at the ARM conferences as part of my overall CRISPR research for years.

1/ I can safely say I feel this is a good management team at this early stage of the game. They are the original CRISPR company holding all the original patents. They also pioneered new technology with chRDNA.

2/ I classify them as cell therapies because that is where their focus is. They have 3 allogeneic CAR-T programs in development while building an iPSC manufacturing for iNK and iT cells.

Read 9 tweets

Biotech2k

@Biotech2k1

3 Oct

Profiling $IPSC:

This is a newer company that recently IPO'd. They are still in the lock up period until mid December. I don't know anything about their management yet. They are working on iPSC cell manufacturing using CRISPR MAD7 editing.

1/ The MAD7 resembles the Cfp1 CAS enzyme. They are focused on developing 2 NK cell programs as their lead programs. They have CNTY-101 which is a standard CD19 and they have CNTY-103 which has CD133.

2/ They are targeting GBM with CNTY-103 which makes this a completely unique program compared to what some other companies are doing. They have some other early CAR-NK and CAR-T programs in development using iPSC.

Read 9 tweets

Biotech2k

@Biotech2k1

3 Oct

Profiling $SANA:

I have only been in $SANA for about 6 months, but I really like their 2 franchises. I also like their management team, although, I don't know them that well.

1/ Their first franchise is the Fusogen programs. This is all about delivering any genetic payload to cells. Their fusogen platform uses virus like particles. If we treated this as a stand alone biotech, I would value it around $1 billion to $1.5 billion.

2/ Their second platform is working to build iPSC manufacturing around hypoimmune cells. This will be right along the lines of what $FATE has built. I would also value this platform around $1 billion to $1.5 billion.

Read 5 tweets

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!